从“肾主骨”到“多器官–骨轴”:中医脏腑理论防治骨质疏松症的系统生物学诠释
From “Kidney Governs Bone” to “Multi-Organ-Bone Axis”: A System Biology Interpretation of Traditional Chinese Medicine Zang-Fu Theory in the Prevention and Treatment of Osteoporosis
DOI: 10.12677/acm.2026.1693095, PDF,   
作者: 舒昂云:黑龙江中医药大学研究生院,黑龙江 哈尔滨;李洪涛*:黑龙江中医药大学附属第一医院骨伤一科,黑龙江 哈尔滨
关键词: 骨质疏松症;多器官–骨轴;肾主骨;脏腑理论;系统生物学;补肾中药;多轴协同;网络调控;Osteoporosis; Multi-Organ-Bone Axis; Kidney Governs Bone; Zang-Fu Theory; System Biology; Kidney-Tonifying Chinese Herbal Medicine; Multi-Axis Synergy; Network Regulation
摘要: 骨质疏松症(OP)的发病机制认知正从“局部骨骼退化”拓展为“全身系统性网络失调”。现代医学提出的“多器官–骨轴”(Multi-Organ-Bone Axis, MOBA)理论,与中医学“整体观念”及“脏腑辨证”在思维逻辑上具有一定的相通。本文以“肾主骨”理论为核心,系统梳理了中医脏腑理论与现代多器官–骨轴的跨学科映射关系:从“肾主骨”到“肾–骨轴”的分子网络互释,从“脾肾互资”到“肠–肾–骨轴”的肠道微生态调控,从“肝肾同源”到“肝–骨轴”的脂代谢–骨代谢对话,从“心肾相交”到“心(脑)–肾–骨轴”的神经内分泌调节,逐层构建了中医多脏协同调控骨代谢的系统生物学诠释框架。在此基础上,进一步探讨了补肾中药通过调控能量代谢与铁死亡、重塑骨免疫微环境、激活肠道菌群及发挥植物雌激素样作用等多途径,实现从单轴解析到多轴协同的网络调控优势,以期为骨质疏松症的中西医结合防治提供新的理论依据。
Abstract: Osteoporosis (OP) is a chronic skeletal disease characterized by low bone mass and microarchitectural deterioration, and the understanding of its pathogenesis is shifting from “local skeletal degeneration” to “systemic network dysregulation”. The “Multi-Organ-Bone Axis” (MOBA) theory proposed by modern medicine is highly consistent with the “holistic concept” and “Zang-Fu syndrome differentiation” of traditional Chinese medicine (TCM) in logical thinking. Taking the “Kidney Governs Bone” theory as the core, this article systematically reviews the interdisciplinary mapping between TCM Zang-Fu theory and the modern MOBA framework: from the molecular network interpretation of “Kidney Governs Bone” to the “Kidney-Bone Axis”, from the gut microbiota regulation of “Spleen-Kidney Mutual Support” to the “Gut-Kidney-Bone Axis”, from the lipid metabolism-bone metabolism dialogue of “Liver-Kidney Common Origin” to the “Liver-Bone Axis”, and from the neuroendocrine regulation of “Heart-Kidney Interaction” to the “Heart (Brain)-Kidney-Bone Axis”, thereby constructing a systems biology interpretive framework for multi-organ synergistic regulation of bone metabolism in TCM. Furthermore, the article explores the multi-pathway mechanisms by which kidney-tonifying herbal medicines achieve network regulation advantages from single-axis analysis to multi-axis synergy, including modulating energy metabolism and ferroptosis, reshaping the bone immune microenvironment, activating gut microbiota, and exerting phytoestrogen-like effects. This study aims to provide a new theoretical basis for the integrated Chinese and Western medicine prevention and treatment of osteoporosis.
文章引用:舒昂云, 李洪涛. 从“肾主骨”到“多器官–骨轴”:中医脏腑理论防治骨质疏松症的系统生物学诠释[J]. 临床医学进展, 2026, 16(9): 682-691. https://doi.org/10.12677/acm.2026.1693095

参考文献

[1] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022) [J]. 中国全科医学杂志, 2022, 26(14): 1671.
[2] Deng, A.-F., Wang, F.-X., Wang, S.-C., Zhang, Y., Bai, L. and Su, J. (2024) Bone-Organ Axes: Bidirectional Crosstalk. Military Medical Research, 11, Article No. 37.
https://doi.org/10.1186/s40779-024-00540-9
[3] Wen, R., Wang, H. and Wang, S. (2026) Deciphering Inter-Organ Communication: The Multi-Organ-Bone Axis in Osteoporosis and Emerging Therapeutic Strategies. Journal of Orthopaedic Translation, 58, Article 101119.
https://doi.org/10.1016/j.jot.2026.101119
[4] 柴勇, 赵宏艳, 刘红, 等. 基于脏腑辨证理论探讨骨质疏松症的中医治疗[J]. 中国中医基础医学杂志, 2019, 25(3): 302-304.
[5] 杨健辉, 曹缈, 陈仁炜, 等. 中药成分调控骨免疫微环境治疗骨质疏松症的研究进展[J]. 现代药物与临床, 2026, 41(4): 1159-1164.
[6] Zaiss, M.M., Jones, R.M., Schett, G. and Pacifici, R. (2019) The Gut-Bone Axis: How Bacterial Metabolites Bridge the Distance. Journal of Clinical Investigation, 129, 3018-3028.
https://doi.org/10.1172/jci128521
[7] Ma, S., Xing, X., Huang, H., Gao, X., Xu, X., Yang, J., et al. (2023) Skeletal Muscle-Derived Extracellular Vesicles Transport Glycolytic Enzymes to Mediate Muscle-to-Bone Crosstalk. Cell Metabolism, 35, 2028-2043.e7.
https://doi.org/10.1016/j.cmet.2023.10.013
[8] Zaidi, M., Yuen, T. and Kim, S. (2023) Pituitary Crosstalk with Bone, Adipose Tissue and Brain. Nature Reviews Endocrinology, 19, 708-721.
https://doi.org/10.1038/s41574-023-00894-5
[9] Babey, M.E., Krause, W.C., Chen, K., Herber, C.B., Torok, Z., Nikkanen, J., et al. (2024) A Maternal Brain Hormone That Builds Bone. Nature, 632, 357-365.
https://doi.org/10.1038/s41586-024-07634-3
[10] 王冰. 黄帝内经素问[M]. 北京: 人民卫生出版社, 1963.
[11] 周俊洁, 黄梓莹, 胡日鹤. 基于肾主骨生髓理论探讨肾性骨病的证治思路[J]. 新中医, 2026, 58(10): 108-113.
[12] 尚奇, 任辉, 沈耿杨, 等. 基于肾主骨生髓理论探讨老年性骨质疏松症的中医治疗[J]. 中医杂志, 2017, 58(16): 1433-1435.
[13] Duan, Y., Zhao, L., Lu, Y., Li, J. and Li, S. (2025) Crosstalk between Kidney and Bones: New Perspective for Modulating Osteoporosis. Ageing Research Reviews, 109, Article 102776.
https://doi.org/10.1016/j.arr.2025.102776
[14] Carullo, N., Sorbo, D., Faga, T., Pugliese, S., Zicarelli, M.T., Costa, D., et al. (2024) Anemia and Mineral Bone Disorder in Kidney Disease Patients: The Role of FGF-23 and Other Related Factors. International Journal of Molecular Sciences, 25, Article 12838.
https://doi.org/10.3390/ijms252312838
[15] 康意. 从肾主骨理论探讨VD-FGF23-Klotho轴与DKD及其中医证候相关性[D]: [硕士学位论文]. 北京: 北京中医药大学, 2023.
[16] Massy, Z.A. and Drueke, T.B. (2020) A New Player in the Kidney-Bone Axis: Regulation of Fibroblast Growth Factor-23 by Renal Glycerol-3-Phosphate. Kidney International, 98, 1074-1076.
https://doi.org/10.1016/j.kint.2020.05.037
[17] 姜刚刚, 漆文霞, 李志婷, 等. 基于“肾主骨”理论探讨中医药干预类风湿关节炎骨破坏与OPG/RANK/RANKL的相关性进展[J]. 风湿病与关节炎, 2022, 11(12): 58-62.
[18] 钦扬, 唐华燕. 从肾-骨-免疫轴探讨系统性红斑狼疮合并骨质疏松的共病机制与中医干预进展[J/OL]. 中国中药杂志: 1-9.
https://link.cnki.net/doi/10.19540/j.cnki.cjcmm.20260518.501, 2026-05-20.
[19] 李杰, 范永升, 丁兴红. 基于“肾主骨”理论探讨解毒祛瘀滋阴方治疗糖皮质激素性骨质疏松的作用机制[J]. 中国中西医结合杂志, 2023, 43(7): 846-850.
[20] 熊梦欣, 朱伟, 邓阿黎, 等. 由成骨细胞糖代谢重编程从“肾痰”论治绝经后骨质疏松症[J]. 中国骨质疏松杂志, 2026, 32(5): 722-726.
[21] 姚乾宁, 李宁, 谢兴文, 等. 从“脾肾互资”辨治骨质疏松症研究进展[J]. 亚太传统医药, 2023, 19(1): 220-223.
[22] Li, L., Ma, L. and Fu, P. (2017) Gut Microbiota-Derived Short-Chain Fatty Acids and Kidney Diseases. Drug Design, Development and Therapy, 11, 3531-3542.
https://doi.org/10.2147/dddt.s150825
[23] Huang, W., Man, Y., Gao, C., Zhou, L., Gu, J., Xu, H., et al. (2020) Short-Chain Fatty Acids Ameliorate Diabetic Nephropathy via GPR43-Mediated Inhibition of Oxidative Stress and NF-κB Signaling. Oxidative Medicine and Cellular Longevity, 2020, 1-21.
https://doi.org/10.1155/2020/4074832
[24] 朱金惠, 王玲, 陶金华, 等. 基于“肠-肾”轴理论的肠道微生态影响慢性肾病发生发展的机制及干预治疗[J]. 南京中医药大学学报, 2023, 39(10): 1054-1062.
[25] Lucas, S., Omata, Y., Hofmann, J., Böttcher, M., Iljazovic, A., Sarter, K., et al. (2018) Short-Chain Fatty Acids Regulate Systemic Bone Mass and Protect from Pathological Bone Loss. Nature Communications, 9, Article No. 55.
https://doi.org/10.1038/s41467-017-02490-4
[26] Wei, J., Liu, Q., Yuen, H., Lam, A.C., Jiang, Y., Yang, Y., et al. (2025) Gut-Bone Axis Perturbation: Mechanisms and Interventions via Gut Microbiota as a Primary Driver of Osteoporosis. Journal of Orthopaedic Translation, 50, 373-387.
https://doi.org/10.1016/j.jot.2024.11.003
[27] 郭海瑞, 田林灵, 张文彬, 等. “肠-骨轴”机制在骨质疏松症与肠道疾病中的相关性研究[J]. 中国骨质疏松杂志, 2023, 29(12): 1851-1855.
[28] 王俊博, 吕敦庆, 潘晓华. 肝骨轴在骨质疏松症中的关键作用[J]. 中国骨质疏松杂志, 2026, 32(3): 441-446.
[29] Han, S., Wei, Y., Yu, G., Jia, W., Liao, W., He, Y., et al. (2026) The Liver-Bone Axis: An Emerging Player in Disease Pathogenesis and Therapeutic Intervention. Science China Life Sciences, 69, 2264-2283.
https://doi.org/10.1007/s11427-025-3207-5
[30] 高城翰, 熊阔海, 杨关林, 等. 基于“肝骨同源”论肝骨轴与老年骨质疏松症伴血脂异常[J]. 中华中医药学刊, 2025, 43(10): 145-147.
[31] Lin, L., Guo, Z., He, E., Long, X., Wang, D., Zhang, Y., et al. (2023) SIRT2 Regulates Extracellular Vesicle-Mediated Liver-Bone Communication. Nature Metabolism, 5, 821-841.
https://doi.org/10.1038/s42255-023-00803-0
[32] 权祯, 秦大平, 张晓刚, 等. 基于“肝主筋、肾主骨”理论探讨OPG/RANKL/RANK信号轴与绝经后骨质疏松症的筋骨相关性[J]. 中国骨质疏松杂志, 2021, 27(6): 890-894.
[33] 赵继荣, 薛旭, 邓强, 等. 基于“肝肾同源”理论的绝经后骨质疏松症病因病机及治疗探讨[J]. 时珍国医国药, 2018, 29(9): 2220-2222.
[34] 欧飞微, 熊曼玲, 解丽菲, 等. 从“肝肾同源”探讨绝经后骨质疏松症的发病机制[J]. 辽宁中医杂志, 2021, 48(7): 52-56.
[35] Gupta, P., Mehrotra, S., Aspera-Werz, R.H., Mairal, A., Pandit, A.H., Nüssler, A.K., et al. (2026) Dynamic Modelling of Liver-Bone Axis: A Microphysiological Approach to Hepatic Osteodystrophy. Bioactive Materials, 58, 505-530.
https://doi.org/10.1016/j.bioactmat.2025.12.011
[36] 韩化伟, 王欣哲, 金杰, 等. 基于“心-肾-骨”轴论治围绝经期骨质疏松[J]. 山东中医杂志, 2025, 44(4): 396-400.
[37] 张泽, 陈巨鹏, 殷松江, 等. 许建安基于“肾-脑-骨轴”理论治疗绝经后骨质疏松症之经验[J]. 江苏中医药, 2026, 58(4): 17-20.
[38] 李龙军. 基于心肾-脑-骨轴探讨滋肾养心方治疗心肾不交型PMOP的疗效观察[D]: [硕士学位论文]. 广州: 广州中医药大学, 2024.
[39] 权祯, 秦大平, 高国栋, 等. 中医“肾虚髓枯”理论介导“下丘脑-垂体-肾上腺轴”在PMOP治疗中的应用进展[J]. 中国骨质疏松杂志, 2023, 29(11): 1621-1625.
[40] 许云腾, 李西海. 从肾-脑-骨轴初探绝经后骨质疏松骨内稳态失衡的机制[J]. 中华中医药杂志, 2020, 35(10): 4797-4800.
[41] 陈莹莹, 江雨, 许淼淼, 等. 基于肾-髓-脑-骨轴探讨骨质疏松症的发病机制[J]. 中医药临床杂志, 2026, 38(3): 449-455.
[42] Wang, S., Guo, M., Yang, B., Fan, T., Zhang, X., Feng, C., et al. (2026) O-Glcnacylation: A Bridge for Regulating the Function of the “Heart-Kidney-Bone Axis”. Biochemistry and Biophysics Reports, 46, Article 102635.
https://doi.org/10.1016/j.bbrep.2026.102635
[43] 陈宇, 孙鑫, 方佳琪, 等. 温补肾阳方药调控线粒体能量代谢改善骨相关细胞的研究进展[J]. 中国骨质疏松杂志, 2026, 32(4): 559-564.
[44] 齐朋朋. 基于“肾主骨”理论骨碎补调控SLC7A11/GPX4轴抑制铁死亡抗骨质疏松的机制研究与临床观察[D]: [博士学位论文]. 济南: 山东中医药大学, 2024.
[45] Jiao, Y., Wang, X., Wang, Q., Geng, Q., Cao, X., Zhang, M., et al. (2023) Mechanisms by Which Kidney-Tonifying Chinese Herbs Inhibit Osteoclastogenesis: Emphasis on Immune Cells. Frontiers in Pharmacology, 14, Article ID: 1077796.
https://doi.org/10.3389/fphar.2023.1077796
[46] 周陈西, 李东, 李开华, 等. 补肾益精方靶向调控SLIT3/ROBO1通路治疗肾精亏虚型原发性骨质疏松症骨形成的机制研究[J]. 中医药信息, 2026, 43(7): 44-51.
[47] Tao, L., Jiang, W., Li, H., Wang, X., Tian, Z., Yang, K., et al. (2024) Single-Cell RNA Sequencing Reveals That an Imbalance in Monocyte Subsets Rather than Changes in Gene Expression Patterns Is a Feature of Postmenopausal Osteoporosis. Journal of Bone and Mineral Research, 39, 980-993.
https://doi.org/10.1093/jbmr/zjae065
[48] Shao, Z., Deng, Q., Cheng, L., Wu, J., Sun, W., Liang, W., et al. (2025) Lactylation-Related Gene AKR1A1 Contributes to Osteoporosis via Metabolic-Immune Regulation: Evidence from Multi-Omics Integration, Single-Cell Transcriptomics, and in Vitro Validation. Frontiers in Immunology, 16, Article ID: 1680305.
https://doi.org/10.3389/fimmu.2025.1680305
[49] Zheng, Z., Yang, F., Ye, X., Jin, Y., Zhu, H., Zhou, X., et al. (2026) Molecular Mechanisms of Polysaccharide Components of Kidney-Tonifying Traditional Chinese Medicine in Regulating Osteoporosis. Frontiers in Pharmacology, 17, Article ID: 1685724.
https://doi.org/10.3389/fphar.2026.1685724
[50] 杨虎, 郑宇, 王通, 等. 中药调节肠道菌群治疗骨质疏松症的研究[J]. 中国骨质疏松杂志, 2026, 32(4): 583-589.
[51] 李昊星, 宋敏, 刘小钰, 等. 淫羊藿有效成分抗骨质疏松作用机制的研究进展[J]. 中国骨质疏松杂志, 2026, 32(4): 608-613.
[52] Duan, Y., Su, Y., Ren, J., Zhou, Q., Tang, M., Li, J., et al. (2023) Kidney Tonifying Traditional Chinese Medicine: Potential Implications for the Prevention and Treatment of Osteoporosis. Frontiers in Pharmacology, 13, Article ID: 1063899.
https://doi.org/10.3389/fphar.2022.1063899
[53] 廖翼涛, 张贤, 李超, 等. 补髓丹治疗老年性骨质疏松症肾阳虚证的临床研究[J]. 中医正骨, 2026, 38(4): 24-32.